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1. Introduction
  Combinatorial use of immunomodulatory agents 
w i th  an t i tubercu los i s  d rugs  ho lds  a  g rea te r 
therapeutic potential for Mycobacterium tuberculosis 
(MTB). Therapeutic vaccines can be combined 
with antituberculosis agents to overcome immune 
tolerance and to selectively induce the body's specific 
and nonspecific immune response, so that a better 
therapeutic goal may be achieved[1]. Heat shock protein 
65(Hsp65) is a highly immunogenic protective antigen 
that is important in MTB infection. The gene vaccine of 
Hsp65 has been widely used in MTB therapy[2]. human 
interleukin 2 (IL-2) plays a key role in cell-mediated 
immunity for intracellular bacteria. It is able to induce 
and activate NK and T cells to produce IFN-毭[3]. IL-6 
can also promote the proliferation of NK and T cells, 
enhance NK cell cytotoxicity, and stimulate the maturity 
of cytolytic T lymphocyte cells[4]. In addition, IL-2 can 
activate macrophages and enhance their killing effect on 
MTB[5]. As such, IL-2 has been successfully used as an 
adjuvant treatment for TB[6]. Based on these published 
data, we hypothesized that a fusion protein containing 
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Hsp65 and IL-2 would provoke a stronger immune 
response against MTB infection.
  In this study, we constructed a Hsp65/IL-2 fusion 
protein and made this protein expressed in recombinant 
Mycobacterium smegmatis (rMS). The ability of the fusion 
protein expressing live vector vaccine to induce immune 
response in mice was examined. The insights from this 
study will lay a foundation for novel treatment approaches 
against TB.
  
2. Materials and methods
2.1. Animals and materials
  Female BALB/c mice of SPF level with a body weight 
of 18-22 g were obtained from the Experimental Animal 
Center of Fourth Military Medical University (Xi 'an, 
China). MTB strain H37Rv was provided by Dr. Rui 
Wang (Institute of Tuberculosis Prevention and Control 
of Shaanxi Province, Xi 'an, China). Bacille Calmette 
Guerin (BCG) vaccine strain was provided by the Lanzhou 
Institute of Biological Products (Lanzhou, China). The 
prokaryotic vector pPRO-Hsp65-hIL-2 containing human 
IL-2 and Hsp65 was supplied by the Fourth Military 
Medical University Experimental Animal Center (Xi 'an, 
China)[7]. Restriction enzymes and DNA ladder DL2000 
were purchased from Takara Company (Dalin, China). 
ADC (Albumin-dextrose-catalase) enrichment and 7H9 
medium were purchased from Difco Company (Detroit, M 
USA). Anti-HSP65 monoclonal antibody was purchased 
from Perfe Scientific (Los Angles, USA). Anti-human 
IL-2 monoclonal antibody was purchased from Lab 
Vision Corporation (Kalamazoo,USA). FITC-labeled goat 
anti-mouse IgG was purchased from Beyotime biology 
and technology (Shanghai, China). Mycobacterium 
smegmatis mc2 155 strain was provided by the Department 
of Microbiology, the Fourth Military Medical University 
(Xi 'an, China). Escherichia coli (E. coli)-Mycobacterium 
shuttle vector pSMT3 was a gift from Professor Marcus A. 
Horwitz (School of Medicine, the University of California, 
Los Angles, USA). All animal experiments were approved 
by the Animal Ethics Committee of the Gansu College of 
Traditional Chinese Medicine (Approval ID: 12002).
2.2. Construction of pSMT3-Hsp65-hIL-2
  The pPRO-Hsp65-hIL-2 plasmid was digested 
with EcoRⅤ and HindⅢ. The target gene fragments 
(Hsp65 and hIL-2) were purified and sub-cloned into 
the E. coli-Mycobacterium expression vector pSMT3 
following treatment with restriction enzymes EcoRⅤ 
and HindⅢ. The target genes containing pSMT3 vectors 
were transformed into E. coli DH5毩 competent cells by 
electroporation (2.5 KV, capacitance 25 毺F, resistance 
1 000 Ω). The bacteria were spread on hygromycin-
containing LB plates for growth. Clones were picked, cut 
with restriction enzymes, and amplified. The purified 
plasmids were digested with EcoRⅤ and HindⅢ and 
the expression of target genes were verified usinging 
1.5% agarose gel electrophoresis. Clones with confirmed 
expression of the target gens were further electroporated 
into 5×106 CFU (colony forming units) of competent cells 
for amplification. The resultant vector designated pSMT3-
Hsp65-hIL-2 was used in the subsequent experiments.
2.3. Generation and identification of recombinant 
Mycobacterium smegmatis strain
  The above-obtained rMS strain were expanded in 7H9 
media at 37 曟 for 3 h, and then grown at 37 曟 for 3 h on 
7H10 plates which were pre-coated with ADC (containing 
glucose, bovine serum albumin factor v, and catalase). 
The recombinant Mycobacterium smegmatis containing 
pSMT3-Hsp65-IL-2 gene (thereafter designated rMS-
Hsp65/IL-2) was obtained by hygromycin selection. 
The positive clones identified by PCR were further 
cultured for 2 days, centrifuged at 10 000 g for 3 min, and 
collected after three washes in sterile saline. Bacterial 
cells were counted using flow cytometry and diluted 
to a concentration of 1×108 CFU per 300 毺L media 
containing 50 毺L normal calf serum. Cells were then 
stained with anti-Hsp65 (diluted at 1:1 000) and anti-IL-2 
(diluted at 1:1 000) monoclonal antibodies at 37 曟 for 30 
min. Cells were centrifuged at 10 000 g for 2 min, washed 
with sterile normal saline, and stained with FITC-labeled 
goat anti-mouse IgG (1:4 000) at room temperature for 15 
min in the dark. After washing for three times in sterile 
normal saline, three 毺L bacterial suspension was taken 
onto a glass slide for observation under the fluorescence 
microscope (Olympus Fluoview BX61, Japan).
2.4. Animal immunization
  Ten female BALB/c mice were subcutaneously injected 
in the dorsal flank with 1×106 CFU of one of the 
following: bacterial cells containing rMS-Hsp65/IL-2 
(1×106 CFU), Mycobacterium smegmatis only, BCG alone, 
and normal saline. Booster injections were given after 3 
weeks.
2.5. Detection of anti-Hsp65 serum specific IgG
  Blood samples were taken at 2, 4, 6, and 8 weeks after 
the initial immunization and the level of antibody against 
anti-Hsp65 was determined by ELISA. Briefly, 96-well 
ELISA plates were coated with 100 毺L of purified Hsp65 
protein (10 毺g/mL) at 4 曟 overnight. Plates were then 
washed with sterile normal saline followed by blocking 
with 1% bovine serum albumin at 37 曟 for 1 h. Into 
each well, 100 毺L of serum sample from each mouse 
was added and the plates were incubated at 37 曟 for 1 
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h. Unconjugated antibodies were removed by washing 
the wells with normal saline. Goat anti-mouse IgG-HRP 
(1:5 000) was added to each well and the plates were 
incubated at 37 曟 for 1 h. The plates were then incubated 
with the substrate solution (O-phenylenediamine) (100 毺
g/mL per well). All the measurements were obtained at 
A450 nm and presented as OD450 nm.
2.6. Isolation of splenic lymphocytes from mice 
  Two weeks following the second immunization, six mice 
from each group were sacrificed by cervical dislocation. 
The spleen was dissociated with several times of syringe 
needle core grinding, and the resultant splenic tissues 
were re-suspended in RPMI-1640 medium. The cell 
suspension was gently added to lymphocyte separation 
medium (at 1:2 ratio) and centrifuged at 1 000 rpm for 20 
min. The lymphocyte rich middle layer was collected and 
washed twice with RPMI-1640.
2.7. Specific lymphocyte proliferation test by MTT assay
  The effect of rMS-Hsp65/IL-2 on the proliferation of 
mouse lymphocytes was examined by standard MTT assay. 
Briefly, the above isolated lymphocytes were cultured at 
a concentration of 1×105/well in 96-well plates in RPMI-
1640 supplemented with 10% fetal calf serum (FCS). Fifty 
毺L of purified Hsp65 protein (25 mg/L in PBS) was then 
added to each well and the plates were incubated at 37 曟 
at 5% CO2 for 68 h. Four hours after addition of 20 毺L/
well of MTT (5 mg/mL in PBS, pH7.2), 150 毺L of DMSO 
was added to each well and incubated for 10 min. Cell 
proliferation was measured by taking the OD reading at 
490 nm. The results were expressed as stimulation index 
(SI), calculated as: SI=OD490 of experimental condition/
OD490 of respective control group.
2.8. Determination of induced cytokines from lymphocytes
  Approximately 4×106 mouse splenic lymphocytes were 
cultured in 24-well plates in RPMI-1640 supplemented 
with 10% FCS. Cells in each well were incubated with 
200 毺L of purified Hsp65 at 5% CO2, 37 曟 for 72 h. The 
culture medium was collected and centrifuged at 5 000 
rpm for 5 min. The supernatant was then stored at -20 曟 
for subsequent measurement for IFN-毭 and IL-2 by 
ELISA kits, according to the manufacturer's instructions 
(Jinmei Biotech Ltd, Shenzhen, China).
2.9. Statistical analysis
  Data in different treatment groups were compared using 
factorial analysis of variance and were expressed as 
mean±standard deviation (SD). A P value of less than 
0.05 was considered statistically significant. 
3. Results
3.1.Verification of successful construction of rMS-Hsp65/
IL-2 by immunofluorescence microscopy and PCR 
  
  We successfully sub-cloned the mycobacterium Hsp65-
IL-2 fusion gene into the expression vector pSMT3. 
Staining of these clones by using specific antibody 
against mouse Hsp65 (Figure 1A) and mouse IL-2 (Figure 
1B) revealed strong green immunofluorescence, indicating 
that these clones express Hsp65 and IL-2, respectively. 
By PCR, the size of the gene product (2 067 bp) by the 
pSMT3-Hsp65-hIL-2 vector is equivalent to that of the 
gene encoding Hsp65-IL-6 fusion protein (Figure 2A). 
Clones containing the pSMT3-Hsp65-hIL-2 vector were 
further cultured in 7H10 plate medium and positive clones 
expanded in 7H9 medium. Analysis of the extracted DNA 
from these clones by PCR showed successful expression 
of the Hsp65 gene fragment (1 620 bp) and IL-2 fragment 
(447 bp) (Figure 2B), confirming that pSMT3-Hsp65-hIL-2 
expresses the Hsp65-hIL-2 fusion gene.  
A B
Figure 1. Construction and verification of the Hsp65/IL-2 fusion 
gene in shuttle vector pSMT3. 
Positive clones from the fusion gene transfected bacterial cells 
were stained for Hsp65 (A) and IL-2 (B). The results were 
observed under fluorescence microscope (magnification: ×100).
M             1                                              M          1           2          3
A B
2 067 bp
447 bp
1 620 bp
Figure 2. Confirmation of Hsp65-IL-2 fusion gene. 
A. The amplified gene products from the sub-cloned pSMT3 vector 
were analyzed by PCR after being cut with the restriction enzyme 
EcoR桋 and Hind栿. M: DNA marker DL2000; Lane 1: pPRO-
Hsp65-IL-2 digested with EcoR桋 and Hind栿. 
B. The 2 067 bp fragment was extracted and further cut with EcoR
桋 and Hind栿, and two gene products with the size of 1 620 bp 
(lanes 1, 2) and 447 bp (lane 3) were generated. These two gene 
products correspond to Hsp65 and Il-2, respectively. M: DNA 
marker DL2000; 1: pPRO-Hsp65-IL-2 digested with EcoR桋 
and Hind栿. Lanes 1, 2: the PCR products for Hsp65 gene; lane 3, 
the PCR product for IL-2.
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3.2. Immunization of mice with rMS-Hsp65/IL-2 induced 
the production of specific antibodies 
  Mice immunized with rMS-Hsp65/IL-2 produced 
much higher level of circulating anti-Hsp65-specific 
IgG, and a time-dependent response was observed (data 
not shown). Four weeks after the second immunization, 
higher level of antibody was detected in the serum of 
mice receiving pSMT-Hsp65-hIL-2 compared to mice 
receiving Mycobacterium smegmatis only or BCG (1:8 
000, 1:2 400, and 1:3 200, respectively, as determined by 
immunohistochemical staining for the respective proteins) 
(P<0.05 between each group).
3.3. rMS-Hsp65/IL-2 increased lymphocyte proliferation
  When spleen lymphocytes isolated from mice 
immunized with rMS-Hsp65/IL-2 positive clones were 
stimulated with Hsp65 antigen, a high stimulation index 
of 3.51 was achieved, which was significantly higher 
than the levels in animals immunized by Mycobacterium 
smegmatis only (stimulation index 1.51) or BCG 
(stimulation index 1.94) (P<0.05, rMS-Hsp65/IL-2 vs. 
Mycobacterium smegmatis group; and P<0.05, rMS-Hsp65/
IL-2 vs.BCG group). These data indicate an increased 
proliferative ability of lymphocytes in response to rMS-
Hsp65/IL-2.
 
3.4. rMS-Hsp65/IL-2 enhanced the production of 
interferon gamma (IFN-毭) and IL-2 by splenic 
lymphocytes
  We next examined the ability of rMS-Hsp65/IL-2 to 
induce the production of cytokines that are important 
for immune response during anti-tuberculosis therapy. 
Splenic lymphocytes from each group of mice were 
cultured in vitro, and the production of IFN-毭 and 
IL-2 were determined by ELISA assay as described 
in the Materials and Methods. Highest level of IFN-
毭 was observed in the splenic lymphocytes from mice 
immunized with rMS-Hsp65/IL-2 [(1 808.00±190.11) pg/
mL], compared to those from Mycobacterium smegmatis 
immunized mice [(800.00±120.12) pg/mL], BCG 
immunized mice [(1 480.00±155.43) pg/mL], and saline 
control group [(120.00±30.83) pg/mL] (P<0.05), rMS-
Hsp65/IL-2 vs. Mycobacterium smegmatis group; and 
P<0.05, rMS-Hsp65/IL-2 vs. BCG group) (Figure 3A).
  Similarly, higher level of IL-2 was observed in the 
splenic lymphocytes from mice immunized with 
rMS-Hsp65/IL-2 [(152.75±12.12) pg/mL] and BCG 
[(148.24±11.88) pg/mL], compared to those from mice 
immunized by Mycobacterium smegmatis [(56.73±12.34) 
pg/mL] (P<0.05) (Figure 3B).
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Figure 3. Generation of IFN-毭 and IL-2 by the splenic 
lymphocytes isolated from mice immunized with different 
constructs.
A:INF, B: IL-2.
4. Discussion
  Mycobacterium smegmatis is a non-toxic mycobacterium 
and has been successfully used in the United States as 
a vaccine adjuvant in the prevention and treatment of 
MTB. The safety and reliability of vector vaccine have 
been documented[8]. Mycobacterium smegmatis grows 10 
times faster than BCG and the MTB-associated proteins 
expressed by Mycobacterium smegmatis are identical 
to the natural MTB proteins in terms of biochemical 
and immunological properties[9]. Single inoculation of 
the Mycobacterium smegmatis live vaccine has been 
shown to provoke sustained induction of target antigens. 
Recombinant Mycobacterium smegmatis live vaccine 
generated by sub-cloning exogenous genes can be 
used for the treatment of MTB infection. The underlying 
mechanisms of recombinant Mycobacterium smegmatis 
therapy include restoration of protective immunity, 
increased generation of H2O2 and nitric oxide by 
monocyte-macrophage cells, and a shift of the immune 
response from Th2 type to Th1-type. These changes 
may facilitate clearance of MTB, particularly the drug-
resistant MTB[10,11].
  In this study, we have demonstrated that a vector 
expressing Hsp65 and human IL-2 fusion protein (rMS-
Hsp65/IL-2) can enhance the body's immune response 
and an immune response shift from Th2-type to Th1 
type[12].
  Our generated rMS-Hsp65/IL-2 vector was found to 
stably overexpresses hIL-2 and Hsp65. When injected 
into mice, this construct was found to induce the 
production of anti-Hsp65-specific IgG antibody. The 
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protein product generated by this vector was shown 
to stimulate the proliferation of the mouse splenic 
lymphocytes. Compared to the classical BCG, rMS-Hsp65/
IL-2 induces a significantly higher proliferation index 
of lymphocytes than BCG. The increased lymphocyte 
proliferative ability was associated with increased 
production of IFN-毭 and IL-2, two important cytokines 
in the MTB induced immunity. Importantly, IFN-毭 is 
considered to be a key cytokine that mediates resistance 
to MTB infection. Increased production of IFN-毭 by the 
splenic lymphocytes provoked by the rMS-Hsp65/IL-2 
may indicate that the Hsp65/IL-2 fusion protein may be 
of value in overcoming the MTB resistance.
  As IFN-毭 is also an important mediator for Th1-type 
cellular immune response[9], increased IFN-毭 production 
by the rMS-Hsp65/IL-2 may likely contribute to the shift 
of Th2-type to Th1-type in response to MTB infection. 
More studies are needed to confirm the direct impact of 
rMS-Hsp65/IL-2 on Th2-type to Th1-type shift.
  In conclusion, our study shows that recombinant live 
vaccine may hold a strong potential to overcome MTB 
resistance. Further exploration of these findings in animal 
models of MTB is warranted.
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